Cell Therapy Product

Our cell therapy product, called PLX-R18, is designed to stimulate the regeneration of damaged bone marrow to produce blood cells lineages following exposure to high levels of radiation, thus preventing lethal hematological damage following exposure while providing regeneration capabilities to the bone marrow.

In addition to potential treatment, we have collaborated with the U.S. Department of Defense to study PLX-R18 as a prophylactic (preventive) treatment for radiation exposure, relevant to first responders, demonstrating 50-70% increase in survival rates.

Our company is also working with Fukushima Medical university since 2015, showing promising data of PLX-R18 in increased survival rates and mitigating severe intestinal damage following radiation exposure.

We would like to suggest a discussion to further introduce the product and its efficacy in mitigating radiation damage.

Our company's PLX-R18 cell therapy was granted an FDA Orphan Drug Designation and the FDA cleared its Investigational New Drug (IND) application for the treatment of ARS in case of nuclear events.

The company has a maturity of cGMP manufacturing (approved by key regulators, mass production).

Potential Business Partners: Pharma Companies, Government Agencies.

Target Countries: USA, European Union Countries.

Company Info:

Year of Establishment: 2003
No.   of Employees:      160